- Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.
- Eli Lilly and Novo Nordisk have both developed anti-obesity drugs, intensifying competition in the weight loss market.
- Eli Lilly raised Zepbound prices in the U.K. and plans to follow price hikes across Europe, while Novo Nordisk received a drug price reduction letter amid Trump administration pressure.
- Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly introducing Mounjaro via the NHS and facing US pricing pressure from Trump.
Eli Lilly and Novo Nordisk are competing in the GLP-1 market, with the new development showing they are also partnering with companies like Becton, Dickinson and Company to provide specialized prefillable syringes for drug delivery.
1 report, 1 independent
Updated Jul 7
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Eli Lilly and Novo Nordisk are competing in the GLP-1 market, with the new development showing they are also partnering with companies like Becton, Dickinson and Company to provide specialized prefillable syringes for drug delivery.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
Novo Nordisk
Danish pharmaceutical company
Related events
- Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.
- Eli Lilly and Company received full FDA approval, expanded a safety study into India, and broke ground on a new facility in Houston while competing in the GLP-1 market.